Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 5Phase 1/2 4Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × Protein Subunit Vaccines × Clear all
NCT00874861 2015-12-08

HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas

University of Pittsburgh

Phase EARLY_PHASE1 Completed
10 enrolled
CNS

Astrocytoma, Neoplasms, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡